Last reviewed · How we verify

NCT02550366

Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI

Terminated Last updated 23 January 2024
What this trial tests

trial testing MRI Contrast in Cardiac Disease in 44 participants. Terminated before completion.

Timeline
1 January 2016
Primary endpoint
19 January 2024
19 January 2024

Quick facts

Lead sponsorUniversity of Minnesota
StatusTerminated
Study typeOBSERVATIONAL
Enrollment44
Start date1 January 2016
Primary completion19 January 2024
Estimated completion19 January 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Minnesota

Who can join

Adults 18 to 80, any sex, with Cardiac Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronary artery disease (CAD) is the leading cause of death in the United States. Cardiac MRI is a non-invasive non-ionizing technique for a comprehensive cardiac exam, which can be used in the diagnosis of CAD. In this work, the investigators will develop and validate techniques for accelerated cardiac MRI, offering better volumetric coverage of the heart, improved contrast, and superior spatial and temporal resolutions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI Contrast

Trials testing the same drug.

Other recruiting trials for Cardiac Disease

Currently open trials in the same condition.

Other University of Minnesota trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02550366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing